Mon Dec 16 13:42:23 UTC 2024: ## Inventurus Knowledge Solutions IPO Oversubscribed by 52 Times on Final Day

**MUMBAI, December 16, 2024** – The initial public offering (IPO) of Inventurus Knowledge Solutions Ltd (IKS Health), a healthcare support services provider, concluded today with a phenomenal oversubscription rate of 52.68 times. Investors bid for 54,61,01,853 shares, significantly exceeding the 1,03,66,780 shares on offer.

This strong demand follows two previous days of robust subscription. By the end of day two, the IPO was already 2.65 times subscribed. Retail Individual Investors (RIIs) demonstrated the most enthusiasm, with their portion oversubscribed by 4.25 times. Non-institutional investors subscribed 3.13 times, while Qualified Institutional Buyers (QIBs) showed interest at 1.89 times oversubscription.

The final day saw an even more dramatic surge in demand. The QIB portion was subscribed 80.64 times, the Non-Institutional Investors (NIIs) portion 23.25 times, and the retail investor portion 14.55 times. The employee portion also saw significant interest.

IKS Health, backed by Rekha Jhunjhunwala and RARE Enterprises, raised ₹1,120 crore from anchor investors prior to the IPO. The IPO, priced between ₹1,265 and ₹1,329 per share, consisted solely of an Offer For Sale (OFS) of existing shares from promoters and shareholders. The company stated its intention to leverage the benefits of a stock exchange listing.

The grey market premium (GMP) reached ₹421 per share, suggesting an anticipated listing price of around ₹1,750, a premium of 31.68% over the upper price band. While GMP is not a reliable indicator of future performance, it reflects investor sentiment.

IKS Health offers a range of services including Revenue Cycle Management (RCM), telehealth support, provider credentialing, data analytics, and Clinical Documentation Improvement (CDI), aiming to streamline administrative tasks for healthcare providers. The company boasts over 800 clients, including prominent US healthcare organizations.

The company’s impressive growth and the expanding US healthcare market, projected to reach USD 6.2 trillion by 2028, contribute to the positive investor outlook. However, analysts caution that the OFS nature of the IPO means the company itself receives no proceeds. The allotment of shares is expected on December 17th, with refunds and crediting of shares to demat accounts on December 18th. Listing on the BSE and NSE is anticipated for December 19th. Several brokerages have given a “subscribe” rating, citing the company’s strong fundamentals and growth potential, although some caution is warranted due to the lack of comparable listed peers.

Read More